Latest news
Debiopharm invests double digit millions in the Canadian startup GenePOC, specialized in the development of rapid diagnostic tests
Debiopharm International SA initiates clinical phase II study evaluating Debio 1143 in Ovarian Cancer
FDA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of ovarian cancer
Yakult Honsha Co., Ltd. and Debiopharm International SA File Patent Infringement for Elplat® against Nippon Kayaku Co., Ltd.
Debiopharm Group™ donates to IMD to promote best practice in family business philanthropy
Debiopharm Investment SA acquires famous Parisian restaurants in partnership with GROUPE BERTRAND and Galiena Capital
Debiopharm International SA announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective…
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.